Search results for " Kidney disease"

showing 10 items of 160 documents

Cardiorenal syndrome type 4: From chronic kidney disease to cardiovascular impairment

2016

Cardiorenal syndrome type 4 (CRS type 4), or chronic renocardiac syndrome, has been defined as "chronic abnormalities in renal function leading to cardiac disease" and recognizes the extreme burden of cardiovascular disease (CVD) risk in patients with chronic kidney disease (CKD). CKD is common and increasingly recognized as a risk factor for CVD. Even though the treatment for CVD has dramatically improved over the past decades, it still takes responsibility for up to 50% of deaths in CKD patients. For this reason, patients with CKD should be thoroughly evaluated for cardiovascular risk factors that require careful management, given the significant burden of CRS type 4 on the healthcare sys…

medicine.medical_specialty030232 urology & nephrologyRenal functionCardiorenal syndromeDisease030204 cardiovascular system & hematologyurologic and male genital diseasesLeft ventricular hypertrophyAtherosclerosis; Cardiorenal syndrome type 4; Cardiovascular risk; Chronic kidney disease; Hypertension; Left ventricular hypertrophy; Atherosclerosis; Cardio-Renal Syndrome; Disease Progression; Humans; Hypertension; Hypertrophy Left Ventricular; Renal Dialysis; Renal Insufficiency Chronic; Risk Factors; Internal Medicine03 medical and health sciences0302 clinical medicineRenal DialysisRisk FactorsInternal medicineChronic kidney diseaseCardiorenal syndrome type 4medicineInternal MedicineHumansIn patientRenal InsufficiencyRenal Insufficiency ChronicRisk factorChronicIntensive care medicineCardio-Renal Syndromebusiness.industryLeft ventricular hypertrophyHypertrophymedicine.diseaseAtherosclerosisCardiovascular riskAtherosclerosis; Cardiorenal syndrome type 4; Cardiovascular riskLeft VentricularRenocardiac SyndromeAtherosclerosiHypertensionCardiologyDisease ProgressionHypertrophy Left VentricularbusinessKidney disease
researchProduct

SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia

2020

Abstract Sodium–glucose co-transporter-2 (SGLT2) inhibitors decreased cardiovascular (CV) events and improved renal outcomes in CV safety studies in type 2 diabetes melitus (T2DM) patients at high CV risk. Canagliflozin also improved kidney outcomes in diabetic kidney disease in the Canagliflozin and Renal Events in Diabetes and Nephropathy Clinical Evaluationtrial. More recently, the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial showed that dapagliflozin improved CV outcomes in patients with HF with or without diabetes. Protection from HF in non-diabetics was confirmed for empagliflozin in the EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Fa…

medicine.medical_specialty030232 urology & nephrologyUrologyRenal functionType 2 diabetes030204 cardiovascular system & hematologyoutcomesNephropathy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDiabetes mellitusClinical endpointMedicineDapagliflozinAcademicSubjects/MED00340Editorial CommentsCanagliflozinTransplantationclinical trialsbusiness.industrySGLT2 inhibitormedicine.diseasemortalitychemistryNephrologybusinesschronic kidney diseaseKidney diseasemedicine.drugClinical Kidney Journal
researchProduct

Epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: a review.

2010

Introduction Cardiovascular diseases are highly prevalent in patients with chronic kidney disease (CKD), and represent the major hazard for mortality in this population. Anomalies of left ventricular (LV) structure and function are very frequent too among CKD patients, and show a negative impact on cardiovascular prognosis. Methods We searched PubMed for manuscripts regarding left ventricular hypertrophy (LVH) in CKD. Definition of LVH was different according to different studies. Results In patients with end-stage renal disease, the prevalence of LVH is higher than 70%. Studies in patients with less advanced CKD have reported increasing prevalence of LVH along with declining renal function…

medicine.medical_specialtyAnemiaPopulationDiastoleRenal functionDiseaseurologic and male genital diseasesLeft ventricular hypertrophyKidneyRisk AssessmentVentricular Function LeftVentricular Dysfunction LeftRisk FactorsInternal medicinemedicinePrevalenceHumanscardiovascular diseasesIntensive care medicineeducationeducation.field_of_studyLeft ventricular dysfunctionbusiness.industryLeft ventricular hypertrophymedicine.diseaseChronic kidney disease.NephrologyHeart failureChronic DiseaseCardiologyDisease ProgressionKidney Failure ChronicHypertrophy Left VentricularKidney DiseasesbusinessKidney diseaseGlomerular Filtration RateJournal of nephrology
researchProduct

The Renal Dangers of an Increased Cardio-Ankle Vascular Index

2020

Although a number of longitudinal investigations assessed the ability of aortic PWV to predict the development of kidney disfunction or progression of renal disease, little is known about the association of CAVI with the risk of renal function deterioration. In the current issue of the American Journal of Hypertension is published a paper of Itano S et al, that add a new piece of evidence in this scenario. The authors analyzed data from the national health check-up system in Japan, including 24.297 participants with normal baseline kidney function. They found that those with CAVI measurements ≥8.1 had a higher risk for CKD events compared to their counterparts with CAVI measurements <8.1…

medicine.medical_specialtyBlood PressurePulse Wave AnalysisKidneyRisk AssessmentVascular StiffnessRisk Factorsarterial stiffneInternal medicineInternal MedicinemedicineHumansAnkle Brachial IndexCardio-ankle vascular indexRenal Insufficiency ChronicKidneybusiness.industrycardio-ankle vascular indexPrognosismedicine.diseasemedicine.anatomical_structurePulsatile FlowHypertensionArterial stiffnessCardiologybusinesschronic kidney diseaseAmerican Journal of Hypertension
researchProduct

SARS-CoV-2 vs. Hepatitis Virus Infection Risk in the Hemodialysis Population: What Should We Expect?

2021

Since the dramatic rise of the coronavirus infection disease 2019 (COVID-19) pandemic, patients receiving dialysis have emerged as especially susceptible to this infection because of their impaired immunologic state, chronic inflammation and the high incidence of comorbidities. Although several strategies have thus been implemented to minimize the risk of transmission and acquisition in this population worldwide, the reported severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence varies across studies but is higher than in the general population. On the contrary, the screening for hepatitis viruses (HBV and HCV) has seen significant improvements in recent years, with va…

medicine.medical_specialtyCOVID19Health Toxicology and Mutagenesismedicine.medical_treatmentPopulation030232 urology & nephrologymedicine.disease_cause03 medical and health sciences0302 clinical medicineRenal DialysisSeroepidemiologic StudiesPandemicHepatitis VirusesmedicineSeroprevalenceHumanshepatitisIntensive care medicineeducationCoronavirusHepatitiseducation.field_of_studybusiness.industryTransmission (medicine)SARS-CoV-2RPublic Health Environmental and Occupational Healthvirus diseasesCOVID-19medicine.diseaseVaccinationEditorialMedicinedialysis030211 gastroenterology & hepatologyHemodialysisbusinesschronic kidney diseaseInternational Journal of Environmental Research and Public Health
researchProduct

Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial

2021

Abstract Aims  Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optimal use of agents that block the renin–angiotensin–aldosterone system, particularly in patients with chronic kidney disease (CKD). In patients with CKD, sodium‒glucose cotransporter 2 (SGLT2) inhibitors provide cardiorenal protection, but whether they affect the risk of hyperkalaemia remains uncertain. Methods and results  The CREDENCE trial randomized 4401 participants with T2DM and CKD to the SGLT2 inhibitor canagliflozin or matching placebo. In this post hoc analysis using an intention-to-treat approach, we assessed the effect of canagliflozin on a composite outcome of time to eith…

medicine.medical_specialtyCardiac & Cardiovascular SystemsINHIBITIONRATIONALEPlaceboHYPERKALEMIAMECHANISMSHyperkalaemiaChronic kidney diseaseInternal medicineDiabetes mellitusType 2 diabetes mellitusEND-POINTSPost-hoc analysismedicineHumansCanagliflozinRenal Insufficiency Chronic1102 Cardiorespiratory Medicine and HaematologySodium-Glucose Transporter 2 InhibitorsCanagliflozinOUTCOMESScience & Technologybusiness.industryType 2 Diabetes Mellitus1103 Clinical Sciencesmedicine.diseaseCardiovascular System & HematologyDiabetes Mellitus Type 2Serum potassiumCardiovascular System & CardiologyPotassiumCardiology and Cardiovascular MedicinebusinessComplicationLife Sciences & BiomedicineSGLT2 inhibitorsKidney diseasemedicine.drugEuropean Heart Journal
researchProduct

New Sub-Phenotyping of Subjects at High Risk of Type 2 Diabetes: What Are the Potential Clinical Implications?

2021

Prediabetes is defined as a condition of abnormal glucose metabolism, characterised by plasma glucose above normal range but not as high as required for the diagnosis of diabetes mellitus (DM). It represents a heterogeneous entity of intermediate glucose metabolism, including impaired fasting glucose, impaired glucose tolerance, and borderline glycated haemoglobin. Prediabetes is being increasingly recognised as an important metabolic state not only predisposing to a higher probability of future progression to DM, but also to an increased risk of different micro- and macrovascular complications. The recently proposed sub-phenotyping of individuals at increased risk of type 2 DM, which disti…

medicine.medical_specialtyCardiovascular disease Diabetes mellitus Kidney disease Precision medicine Prediabetes Type 2 diabetes mellitusEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologyImpaired glucose tolerance03 medical and health sciencesDiabetes mellitus0302 clinical medicineDiabetes mellitusInternal medicineType 2 diabetes mellitusInternal MedicineMedicinePrediabetesDisease burdenbusiness.industryPrecision medicineType 2 Diabetes MellitusKidney diseaseCardiovascular diseasemedicine.diseaseImpaired fasting glucoseCommentarybusinessPrediabetesKidney diseaseDiabetes Therapy
researchProduct

Heart failure and chronic kidney disease in a registry of internal medicine wards

2014

Background: The aim of the present study was to evaluate the association between heart failure (HF) and chronic kidney disease (CKD) in tertiary care centers using the clinical records of patients enrolled in internal medicine departments.Patients and methods: We used the clinical records of 1380 elderly patients to identify patients with a history of HF and CKD using admission ICD codes and glomerular filtration rate (GFR) formulas. Magnitude and strength of such associations were investigated by univariable and multivariable analysis.Results: Of the 1380 patients enrolled, 27.9% had HF (age 80 ± 7, BMI 27 ± 6 kg/m2) and 17.4% CKD (age 81 ± 7, BMI 26.8 ± 6 kg/m2). Both groups were signific…

medicine.medical_specialtyChronic kidney disease; Elderly; Heart failure; REPOSI; Gerontology; Geriatrics and GerontologyHeart failure; Elderly; Chronic kidney disease; REPOSIChronic kidney disease; Elderly; Heart failure; REPOSI; Humans; Sleep Apnea Syndromes; Noninvasive Ventilation; Gerontology; Geriatrics and GerontologyChronic kidney disease; Elderly; Heart failure; REPOSIRenal functionHeart failure; chronic kidney disease; elderly; registry; REPOSIHeart failureregistryTertiary careSleep Apnea SyndromeElderlySleep Apnea SyndromesInternal medicineChronic kidney diseaseEpidemiologymedicineHumansNoninvasive Ventilationbusiness.industryREPOSIChronic kidney disease; Elderly; Heart failure; REPOSI; Humans; Sleep Apnea Syndromes; Noninvasive Ventilation; Geriatrics and Gerontology; Gerontologymedicine.diseaseHeart failureHeart failure Elderly Chronic kidney disease REPOSIIcd codesGeriatrics and GerontologybusinessClinical recordBody mass indexGerontologyKidney diseaseHuman
researchProduct

Chronic kidney disease and dialysis therapy: incidence and prevalence in the world

2021

Сhronic kidney disease (CKD) is the important public and medical problem in the world because of a large burden on health care systems. The prevalence of CKD and number of dialysis patients are increasing in the world. The prevalence and incidence of CKD depends on age, race, and gender of patients, region, and the presence of the CKD registry in a country. Diabetes mellitus (DM) and arterial hypertension (AH) are the most common causes of end stage renal disease (ESRD). It is projected that the number of dialysis patients will reach 5.5 million in 2030. Specific strategies and interventions should be urgently aimed at reducing in the burden of CKD by means of the prevention, detection and …

medicine.medical_specialtyDialysis Therapyhemodialysisbusiness.industryIncidence (epidemiology)030232 urology & nephrologyPharmaceutical SciencePharmacymedicine.diseaseurologic and male genital diseasesfemale genital diseases and pregnancy complicationsRS1-44103 medical and health sciences0302 clinical medicinePharmacy and materia medicaperitoneal dialysisInternal medicinemedicinePharmacology (medical)030212 general & internal medicinebusinesschronic kidney diseaseKidney diseaseFarmatsija
researchProduct

Sodium-Lithium Countertransport in Autosomal Polycystic Kidney Disease

1997

medicine.medical_specialtyEndocrinologybusiness.industryInternal medicinePolycystic kidney diseaseMedicineSodium lithium countertransportbusinessmedicine.disease
researchProduct